Deficient activation of CD95 (APO-1/ Fas)-mediated apoptosis: a potential factor of multidrug resistance in human renal cell carcinoma
暂无分享,去创建一个
P. Krammer | Martina Müller | C. Gerharz | C. Mahotka | H. Gabbert | M. Müller | T. Kalinski | U. Ramp | M. Wenzel | I. Lorenz | M. Déjosez | B. Czarnotta | Ingrid Lorenz
[1] D. Israeli,et al. p53 Activates the CD95 (APO-1/Fas) Gene in Response to DNA Damage by Anticancer Drugs , 1998, The Journal of experimental medicine.
[2] D. Ferrari,et al. Apoptosis signaling by death receptors. , 1998, European journal of biochemistry.
[3] S. Fulda,et al. Chemosensitivity of solid tumor cells in vitro is related to activation of the CD95 system , 1998, International journal of cancer.
[4] M. Peter,et al. Two CD95 (APO‐1/Fas) signaling pathways , 1998, The EMBO journal.
[5] H. Miyake,et al. p53 modulation of Fas/Apo-1 mediated apoptosis in a human renal cell carcinoma cell line. , 1998, International journal of oncology.
[6] S. Hetts. To die or not to die: an overview of apoptosis and its role in disease. , 1998, JAMA.
[7] A. Hirose,et al. Expression of Fas in renal cell carcinoma. , 1997, Japanese journal of clinical oncology.
[8] R. Figlin,et al. Renal cell carcinoma: recent progress and future directions. , 1997, Cancer research.
[9] S. Fulda,et al. Deficient activation of the CD95 (APO-1/Fas) system in drug-resistant cells , 1997, Leukemia.
[10] I. Herr,et al. The CD95 (APO-1/Fas) system mediates drug-induced apoptosis in neuroblastoma cells. , 1997, Cancer research.
[11] C. Gerharz,et al. Acquisition of TGF-beta 1 resistance: an important progression factor in human renal cell carcinoma. , 1997, Laboratory investigation; a journal of technical methods and pathology.
[12] N. Baldini. Multidrug resistance — a multiplex phenomenon , 1997, Nature Medicine.
[13] P. Galle,et al. Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53. , 1997, The Journal of clinical investigation.
[14] T. Miki,et al. Fas/APO-1-mediated apoptosis of human renal cell carcinoma. , 1996, Biochemical and biophysical research communications.
[15] P. Galle,et al. Lymphocyte apoptosis induced by CD95 (APO–1/Fas) ligand–expressing tumor cells — A mechanism of immune evasion? , 1996, Nature Medicine.
[16] R. Moll,et al. Chromophilic renal cell carcinoma: cytomorphological and cytogenetic characterisation of four permanent cell lines. , 1996, British Journal of Cancer.
[17] E. Russell,et al. Fas expression and function in normal and malignant breast cell lines. , 1996, Cancer research.
[18] S. Chouaib,et al. The renal cell carcinoma lysis by a specific cytotoxic T cell clone is independent of the Fas/Fas-L cytotoxic pathway. , 1996, Tissue antigens.
[19] V. Bilim,et al. Tetrapeptide DEVD‐aldehyde or YVAD‐chloromethylketone inhibits Fas/Apo‐1 (CD95)‐mediated apoptosis in renal‐cell‐cancer cells , 1996, International journal of cancer.
[20] F. Shanahan,et al. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand , 1996, The Journal of experimental medicine.
[21] J. Beijnen,et al. Clinical Pharmacokinetics of Topotecan , 1996, Clinical pharmacokinetics.
[22] I. Herr,et al. Involvement of the CD95 (APO–1/Fas) receptor/ligand system in drug–induced apoptosis in leukemia cells , 1996, Nature Medicine.
[23] K. Kinzler,et al. p21 is necessary for the p53-mediated G1 arrest in human cancer cells. , 1995, Cancer research.
[24] M. Peter,et al. Cytotoxicity‐dependent APO‐1 (Fas/CD95)‐associated proteins form a death‐inducing signaling complex (DISC) with the receptor. , 1995, The EMBO journal.
[25] M. Peter,et al. APO-1 (CD95)-dependent and -independent antigen receptor-induced apoptosis in human T and B cell lines. , 1995, International immunology.
[26] G. Natoli,et al. Resistance to Fas-mediated apoptosis in human hepatoma cells. , 1995, Oncogene.
[27] M. Sehested,et al. Characterisation of a human small-cell lung cancer cell line resistant to the DNA topoisomerase I-directed drug topotecan. , 1995, British Journal of Cancer.
[28] K. Uoto,et al. A New Water‐soluble Camptothecin Derivative, DX‐8951f, Exhibits Potent Antitumor Activity against Human Tumors in vitro and in vivo , 1995, Japanese journal of cancer research : Gann.
[29] J. Roth,et al. Wild-type human p53 and a temperature-sensitive mutant induce Fas/APO-1 expression , 1995, Molecular and cellular biology.
[30] S. Störkel,et al. Establishment and characterization of two divergent cell lines derived from a human chromophobe renal cell carcinoma. , 1995, The American journal of pathology.
[31] G. Fiucci,et al. Three functional soluble forms of the human apoptosis-inducing Fas molecule are produced by alternative splicing. , 1995, Journal of immunology.
[32] S. Nagata,et al. Apoptosis regulated by a death factor and its receptor: Fas ligand and Fas. , 1994, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.
[33] J. Trent,et al. WAF1, a potential mediator of p53 tumor suppression , 1993, Cell.
[34] W. Linehan,et al. Chromosome 17p deletions and p53 mutations in renal cell carcinoma. , 1993, Cancer research.
[35] S. Störkel,et al. Ultrastructural appearance and cytoskeletal architecture of the clear, chromophilic, and chromophobe types of human renal cell carcinoma in vitro. , 1993, The American journal of pathology.
[36] L. Grochow,et al. Effect of P-glycoprotein expression on the accumulation and cytotoxicity of topotecan (SK&F 104864), a new camptothecin analogue. , 1992, Cancer research.
[37] R. Shoemaker,et al. Model for estimation of clinically achievable plasma concentrations for investigational anticancer drugs in man. , 1986, Cancer treatment reports.
[38] T. Mosmann. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. , 1983, Journal of immunological methods.
[39] E. A. Linehan. To Die or Not To Die , 1951, The Hastings Center report.
[40] M. Takiguchi,et al. Fas-independent apoptosis of T cells via killer cell inhibitory receptors. , 1998, International immunology.
[41] U. M. Moll,et al. p53--an acrobat in tumorigenesis. , 1998, Critical reviews in oral biology and medicine : an official publication of the American Association of Oral Biologists.
[42] P. Krammer. The tumor strikes back: New data on expression of the CD95(APO-1/Fas) receptor/ligand system may cause paradigm changes in our view on drug treatment and tumor immunology , 1997, Cell Death and Differentiation.
[43] Y. Homma,et al. Effect of alpha-interferon alone and combined with other antineoplastic agents on renal cell carcinoma determined by the tetrazolium microculture assay. , 1994, European urology.
[44] R. Mirimanoff,et al. Clinical implications of the p53 tumor-suppressor gene. , 1994, The New England journal of medicine.
[45] P. Alken,et al. P-170 glycoprotein, glutathione and associated enzymes in relation to chemoresistance of primary human renal cell carcinomas. , 1990, Urologia internationalis.